Overview / Abstract: |
Treatment for patients with X-linked hypophosphatemia (XLH) has long been hindered by conventional agents’ monitoring requirements, adverse events, and limited efficacy. Fortunately, in April 2018, an FGF23 blocking antibody became the first FDA-approved agent for XLH. However, because XLH remains a rare disease, clinicians may not be properly equipped to recognize and manage it. This CME activity, X-Linked Hypophosphatemia: Improving Clinician Awareness and Management, will help participants recognize the clinical presentation of XLH, identify the potential short- and long-term complications of XLH, and understand the latest evidence on and role of the recently approved breakthroughs. |
Expiration |
Sep 05, 2020 |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 AMA PRA Category 1 Credit; 1.0 American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) point(s); 1.00 Prescribed credit(s) by the American Academy of Family Physicians (AAFP); 1.0 American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) point(s) |
Accreditation |
Accreditation Council for Continuing Medical Education (ACCME) |
Presenters / Authors / Faculty |
Suzanne Jan De Beur, MD Farzana Perwad, MD |
Sponsors / Supporters / Grant Providers |
This program is supported by an educational grant from Ultragenyx. |
Keywords / Search Terms |
Rockpointe Rockpointe, CME, Free CME, Continuing Medical Education, CME Webcourse, On-Demand CME, Free CE, X-Linked Hypophosphatemia, FGF23 blocking antibody, primary care, clinicians, family physicians, pediatricians, internists, internal medicine Free CE CME |